Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1128 Results

Title
Intervention Indication Therapeutic Area Year Actions
Avalglucosidase alfa for late-onset Pompe disease Avalglucosidase alfa (neoGAA; GZ-402666) Pompe disease Endocrine Nutritional and Metabolic Disorders , Genetic Disorders 2019 View  |  Download
Avacopan in addition to standard of care for ANCA-associated vasculitis Avacopan (CCX168) Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) Cardiovascular System , Immunology 2018 View  |  Download
Avacincaptad pegol for the treatment of geographic atrophy secondary to age-related macular degeneration Avacincaptad pegol Age-related macular degeneration (AMD) , Geographic atrophy Ophthalmology 2023 View  |  Download
Atogepant for prevention of migraine Atogepant (AGN-241689; MK-8031) Migraine Neurology 2022 View  |  Download
Atezolizumab with platinum-based chemotherapy and bevacizumab for epithelial ovarian cancer or fallopian tube cancer or primary peritoneal cancer Atezolizumab (Tecentriq; MPDL3280A) , Bevacizumab (Avastin; R 435; RG 405; RG 435) , Chemotherapy Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2022 View  |  Download
Atezolizumab with paclitaxel and carboplatin for previously untreated advanced endometrial cancer Atezolizumab (Tecentriq; MPDL3280A) , Carboplatin (Paraplatin) , Paclitaxel (Taxol; paclitaxel albumin) Endometrial cancer Female Reproductive Cancer 2023 View  |  Download
Atezolizumab with chemotherapy for treating recurrent triple-negative breast cancer Atezolizumab (Tecentriq; MPDL3280A) , Chemotherapy Breast cancer Breast Cancer 2022 View  |  Download
Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-containing chemotherapy and one programmed death-ligand 1 checkpoint inhibitor Atezolizumab (Tecentriq; MPDL3280A) , Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2022 View  |  Download
Atezolizumab with cabozantinib for previously treated metastatic castration-resistant prostate cancer Atezolizumab (Tecentriq; MPDL3280A) , Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) Prostate cancer Male Reproductive Cancer 2022 View  |  Download
Atezolizumab with cabozantinib for advanced renal cell carcinoma after 1 therapy Atezolizumab (Tecentriq; MPDL3280A) , Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) Renal cell carcinoma (RCC) Renal Cancer 2022 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications